Do cancers arise from a single transformed cell or is monoclonality of tumours a late event in carcinogenesis? by Alexander, P.
Br. J. Cancer (1985), 51, 453-457
Commentary
Do cancers arise from a single transformed cell or is
monoclonality of tumours a late event in
carcinogenesis?
This issue contains the abstracts of a recent informative and stimulating symposium on
the clonal evolution of tumours. Evidence that the great majority of the cells within a
malignant lesion or leukaemia derive from a single precursor cell, i.e. are monoclonal in
origin, can be of great value in diagnosis, particularly in the case of lymphoid
malignancy where it provides proof that the proliferation is neoplastic rather than a
reactive response of lymphocytes. It is however, less clear what a finding of mono-
clonality tells us about the genesis of the malignant lesion and in particular whether the
occurrence in an animal of a single cell having a full transformed phenotype is sufficient
to initiate a malignant lesion. It is appropriate to point out that this proposition was
made very precisely 71 years ago by Boveri (1941).
The first thing to note is that the oft repeated finding that the malignant cells of a
tumour exhibit wide phenotypic and karyotypic heterogeneity is not incompatible with
the concept that they all derive from a single transformed cell. The heterogeneity of the
cancer cells comprising a tumour stems from karyotypic instability which is perhaps the
most characteristic difference between cancer and normal cells. Not only is a failure in
mitosis to share chromosomes equally between the two daughter cells much more
frequent for malignant than for normal cells but in the case of malignant cells the
progeny of unequal division commonly retain the capacity of unlimited proliferation
and consequently must be heterogenous in phenotype.
The most compelling evidence for monoclonality comes from analyses of the gene
products of malignant cells and these may be located on the surface, within the cell or
secreted. With tumours of B-cell lineage, monoclonality is most easily established by the
fact that all cells synthesise the same immunoglobulin. Recently the demonstration of
unique DNA rearrangements of the antigen receptors has proved the monoclonality of
most T-cell malignancies so far studied. For non-lymphoid cancers, studies of clonality
have been based on the mosaicism which exists in normal tissues of women hetero-
zygous for the two alleleic forms of the enzyme glucose-6-phosphate dehydrogenase, the
gene for which is on the X-chromosome. The cells from tumours of such women are
usually-though not invariably-composed predominantly of one of the alleles and
therefore monoclonal. The existence of a specific karyotypic abnormality in all of the
cells of a cancer or leukaemia have also been claimed as showing a clonal origin, but in
view of the findings that a particular chromosome abnormality may be related to a
particular malignancy, renders this type of evidence less convincing as evidence for
monoclonality than the analysis of gene products. Taken together these studies suggest
that many, if not most, cases of human cancer and leukaemia are monoclonal. It is
tempting to interpret this as supporting both a clonal origin and the hypothesis that
cancer is the consequence of a very rare and heritable event involving a single cell only.
In other words the cause is a mutation or a sequence of mutations induced in one
somatic cell.
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In view of the large numbers of cells which are at risk in an adult organism and the
relative rarity of cancer, mutations resulting in transformation would be expected to be
extremely infrequent. Yet in vitro transformation of mammalian cells into a phenotype
capable of growing as malignant tumours when transplanted into animals occurs
remarkably readily and in tissue culture the transformation of normal cells to ones
which exhibit malignant characteristics is far from being very rare or infrequent.
Because of the ease of dosimetry this is most readily demonstrated for the carcinogenic
effect of ionising radiations (Borek, 1982) although the same applies to chemical
carcinogens or indeed "spontaneous" transformation. One Gray of X-rays given to
embryonic cells in tissue culture causes of the order one cell in 104 to be transformed
and after clonal expansion such a transformed cell will grow as a tumour in vivo. Yet
clearly the carcinogenicity of X-rays for intact animals is many orders of magnitude less
than would follow from the induction at the rate observed in vitro of a single malignant
cell when one considers the number of cells capable of being transformed.
The discrepancy between the rate of induction of cancer in animals and of
transformation of cells in vitro was seen by Burnet (1970) as evidence for the existence
in animals of a mechanism which results in the selective destruction of cells exhibiting a
transformed phenotype. Burnet was a most persuasive advocate of the hypothesis that
specific T-cell acquired immunity was responsible for surveillance of potentially
malignant cells but sadly experience with animals (and immunosuppressed patients)
failed to reveal an increase in cancer incidence except when this could be directly
attributable to viruses of DNA type when the surveillance was that of the viral infection
as well as of the transformed cells (cf. Stutman, 1975). More recently the role of
eliminating transformed cells has been allocated to so call non-specific immune
processes exerted by leukocytes and especially NK cells. However, as with surveillance
by T-cells direct experimental data fails to support this concept (Fodstad et al., 1984).
A way out of the conflict between the ease of cell transformation in vitro and the
rarity of tumours in vivo is to abandon the concept that tumours arise from a single
cell. The finding of monoclonality in clinically detectable cancer and leukaemia when
more than 1010 cancer cells are present does not mean that initially the cancer arose
from a single cell. Initially the malignant proliferation could be polyclonal and
monoclonality could be a late event due to selection of cells from the different
clones. Indeed, in chemically induced sarcomas of mice Woodruff et al. (1982) have
documented instances in which an originally polyclonal tumour progressively became
monoclonal.
I propose to explore the concept that the initiation of tumour growth in vivo requires
the participation of several independently transformed cells and that it is only when a
minimum number of transformed cells come together that they create a micro-
environment which permits their unlimited proliferation and the production of a
malignant lesion. This model would account for the finding that tumours arise very
much less frequently in vivo than would correspond to the occurrence of transformation
at the cellular level in vitro of a culture system containing a comparable number of
cells. However, why should a single transformed cell be competent to grow as a clone in
vitro whereas in vivo in the tissue in which it originates it does not proliferate? This
situation is not as absurd as it at first appears because in an animal a cell that has
undergone transformation to malignancy has to grow in the environment of extra
cellular fluid which in composition resembles plasma whereas in cell culture clonal
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the many substances released from platelets on clotting which include potent growth
factors which have been directly implicated in the cell proliferation inherent in wound
healing. In vitro f'ibroblasts divide in the presence of serum and in vivo in response to
injury resulting in blood clotting when the equivalent to serum is present (Ross et al.,
1978).
To extend this argument to malignant cells requires the acceptance of autocrine
stimulation as suggested by Sporn and Todaro (1980). The premise is that for cancer
cells, as for normal cells, proliferation is not the norm but occurs in response to a
sequence of polypeptide growth factors which bind to high affinity membrane receptors.
While in healthy tissue in general one cell synthesises the growth factors required by
another (some of the growth factors only act locally at the site of production), a
characteristic of cancer cells is that they constitutively synthesise growth factors
(referred to as transforming growth factor, TGF) for which they have membrane
receptors and to which they themselves respond.
However, the process of autocrine stimulation does not in general operate at the level
of an individual cell. Thus in vitro malignant cells will only grow in serum free media if
the initial cell concentration is high and growth in serum free medium from low cell
inocula requires the addition of growth factors such as TGFs either extracted from
cancer cells or found in the supernatants from dense cultures of tumour cells (Kaplan &
Ozanne, 1983). Apparently the process of autocrine stimulation can be interrupted
because the binding of the TGFs to the cells that produces them is not tightly coupled.
Presumably the concentration of TGF around an isolated cell is not sufficient to be
mitogenic because the TGF diffuses away from the cell environment before it has
bound to the receptor. A concentration of TGF sufficient for proliferation in vitro in
the absence of serum is only achieved in cultures containing relatively high cell
concentrations. In serum clonal growth is possible because co-operation between a
number of transformed cells is not required as the need for an adequate amount
of TGF has been by-passed. When the artefact of serum has been eliminated the
conflict that a single transformed cell can grow in vitro but not in vivo is resolved.
The concept that cancer cells, that have not undergone powerful selection by
prolonged passage, are not capable of giving rise to a tumour from a single cell and
that the true autonomy of cancer requires a cluster of malignant cells which have to
create a micro-environment adequate for proliferation would at first sight appear to be
in conflict with blood borne metastasis. While tumour emboli consisting of more than
one cancer cell give rise more frequently than single cells to lung metastases, there can
be little doubt that single cells are capable of causing blood borne metastasis, especially
in organs other than the lung to which they must have gained access via the arterial
circulation. However one of the most striking aspects of the metastatic process is the
peculiarity of the relative frequencies of metastases in different organs. This cannot be
explained by haemodynamic factors and the concept of Paget (1889) that particular
organs provide expecially favourable soil for tumour emboli which he likened to seed
has found powerful support from clinical post mortem studies (cf. Willis, 1967). These
show that cancer cells that have passed beyond the lung into the arterial circulation
grow selectively in certain organs. In experimental animals organ preference can be
demonstrated by injecting cancer cells into the left ventricle (so as to avoid the filtering
effect of the lung which arises if cells are given intravenously) whence they are
distributed via the arterial circulation to all of the organs. Several investigations had
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which received the majority of the blood, but occurred instead in adrenal, bone, ovary
and other organs that took only a small fraction of the cardiac output.
We have made a detailed study of the initial distribution, trapping, cell death and
eventual incidence of metastases for three histologically different rat tumours following
intracardiac injection of their cells (Murphy et al., 1985). In our studies the proportion
of the cells arrested in different organs paralleled the blood flow to the organs (i.e. the
cells went where the blood went) but the probability that a cancer cell deposited in an
organ causes a macroscopic metastasis varied very widely between different organs.
Thus, one out of ten cells trapped in the adrenal caused a metastasis whereas in skeletal
muscle the figure was one in 105. This organ preference does not have an immuno-
logical basis as the same distribution is seen in genetically athymic (nu/nu) rats and rats
immunosuppressed with cyclosporin A. We (Alexander et al., 1985) have speculated
that an isolated cancer cell is not capable of autonomous growth unless it finds itself in
a tissue capable of supplying it with growth factors which act like TGFs, or which
potentiate TGF. Once growth has started it will be self sustaining since a cluster of
cancer cells will ensure the necessary concentration of TGF in the fluid around the
metastasis.
The existence of dormant metastases in organs distant from the primary tumour
could be similarly explained (Alexander, 1983). In animal models the presence in the
lung of dormant cancer cells which stemmed from blood borne spread from a distant
primary tumour could be demonstrated by transplantation. In the lung the cells do not
grow but when a cell suspension from the lung taken from animals from which the
"primary" had been surgically removed a week previously, is injected into the
peritoneal cavity then tumours indistinguishable from the "primary" grow out.
In view of the synergy between some tumour promoters, such as the phorbal esters,
and polypeptide growth factors (Dicker & Rozengurt, 1978) it is conceivable that one
part of the promotional component of carcinogenesis is that the promoter makes
possible the proliferation in vivo of single or small numbers of transformed cells which
in the absence of the promoter would not proliferate because the local TGF concen-
tration is too low. Indeed, Rous's strategy when looking for a promotional phase
in skin carcinogenesis was to induce division of initiated cells. (cf. Friedewald & Rous,
1944). Also, the concept that more than one cell needs to undergo transformation
before a tumour can develop is in some ways a re-expression of theories which saw
cancer as a generalised tissue disorder. The evidence for this is compelling for bladder
carcinoma and attention has recently been drawn to this old concept by Rubin (1984)
in a critical analysis of the role of mutational events in carcinogenesis. I conclude that
recent discoveries in the field of polypeptide growth factors and in particular their
constitutive synthesis by malignant cells provides a biological framework in which the
clonal growth of malignant cells in vitro can be reconciled with a hypothesis that in
general tumours occurring in animals are not clonal in origin, but that their genesis
requires the interaction and co-operation of several transformed cells. The mono-
clonality of macroscopic tumours need not reflect a clonal state at early stages of
tumour development, so much as the cumulative effect of selective pressures upon
polyclonal populations during active growth.
P. Alexander
CRC Medical Oncology Unit, University of Southampton, Southampton General Hospital,
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